Publications by authors named "Ryan L Setten"

Claim this Profile
D
Design, Synthesis, and Biochemical Analysis of a Molecule Designed to Enhance Endosomal Escape.
Satish G Jadhav, Ryan L Setten, Carlos Medina, Xian-Shu Cui, Steven F Dowdy

AAPS J· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delivery of RNA Therapeutics: The Great Endosomal Escape!
Steven F Dowdy, Ryan L Setten, Xian-Shu Cui, Satish G Jadhav

Nucleic Acid Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA/RNA heteroduplex oligonucleotides: An unanticipated twist in the delivery of ASOs.
Ryan L Setten, Steven F Dowdy

Mol Ther Nucleic Acids· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRED9: a differentially expressed elncRNA regulates expression of transcription factor CEBPA.
Ryan L Setten, Pritsana Chomchan, Elizabeth W Epps, John C Burnett, John J Rossi

RNA· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: The current state and future directions of RNAi-based therapeutics.
Ryan L Setten, John J Rossi, Si-Ping Han

Nat Rev Drug Discov· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: The current state and future directions of RNAi-based therapeutics.
Ryan L Setten, John J Rossi, Si-Ping Han

Nat Rev Drug Discov· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The current state and future directions of RNAi-based therapeutics.
Ryan L Setten, John J Rossi, Si-Ping Han

Nat Rev Drug Discov· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.
Ryan L Setten, Helen L Lightfoot, Nagy A Habib, John J Rossi

Curr Pharm Biotechnol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent inhibition of ABL tyrosine kinase causes enhanced apoptotic response to TRAIL and disrupts the pro-apoptotic effect of chloroquine.
Priya Sridevi, May K Nhiayi, Ryan L Setten, Jean Y J Wang

PLoS One· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis